Ozmosi | Carboplatin Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

Carboplatin

Alternative Names: carboplatin, paraplatin, cbdca, carboplatine, carboplatinum, PTC-Ptz
Clinical Status: Inactive
Latest Update: 2026-02-05
Latest Update Note: News Article

Product Description

Carboplatin interferes with the development of the genetic material in a cell, the DNA. This stops it from dividing into 2 new cells and kills it. Carboplatin is a chemotherapy treatment for many different types of cancer. (Sourced from: https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/drugs/carboplatin)

Mechanisms of Action: DNA Synthesis Inhibitor, Mitosis Inhibitor, Tubulin Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Hoffmann-La Roche
Company Location:
Company CEO: Severin Schwan
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Carboplatin

Countries in Clinic: Argentina, Australia, Austria, Belarus, Belgium, Bosnia, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Cuba, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Georgia, Germany, Greece, Hong Kong, Hungary, India, Ireland, Israel, Italy, Japan, Kazakhstan, Korea, Latvia, Malaysia, Mexico, Moldova, Montenegro, Morocco, Netherlands, New Zealand, Norway, Panama, Peru, Philippines, Poland, Portugal, Puerto Rico, Qatar, Romania, Russia, Saudi Arabia, Serbia, Singapore, Slovakia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States, Unknown Location, Vietnam

Active Clinical Trial Count: 223

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Adenocarcinoma|Anal Cancer|Bladder Cancer|Breast Cancer|Carcinosarcoma|Cervical Cancer|Clear Cell Adenocarcinoma|Clear Cell Sarcoma|Diffuse Large B-Cell Lymphoma|Endometrial Cancer|Endometrioid Carcinoma|Esophageal Cancer|Fallopian Tube Cancer|Gastrointestinal Cancer|Glioblastoma|Head and Neck Cancer|Hodgkin Lymphoma|Inflammatory Breast Cancer|Lymphoma, B-Cell|Lymphoma, Non-Hodgkin|Mesothelioma|Mixed Tumor, Mullerian|Nasopharyngeal Cancer|Non-Small-Cell Lung Cancer|Nose Cancer|Other|Ovarian Cancer|Pain Unspecified|Peritoneal Cancer|Prostate Cancer|Retinoblastoma|Serous Cystadenocarcinoma|Small Cell Lung Cancer|Squamous Cell Carcinoma|Tobacco Use Disorder|Transitional Cell Carcinoma|Triple Negative Breast Cancer|Unilateral Breast Cancer|Uterine Cancer

Phase 2: Adenoid Cystic Carcinoma|Anus Cancer|Brain Cancer|Carcinoma, Adenosquamous|Colorectal Cancer|Edema|Erythema|Gliosarcoma|Laryngeal Cancer|Lip Cancer|Lung Cancer|Male Breast Cancer|Mouth Cancer|Neoplastic Cells, Circulating|Neuroendocrine Carcinoma|Oncology Solid Tumor Unspecified|Oncology Unspecified|Oropharyngeal Cancer|Pancreatic Cancer|Pancreatic Ductal Carcinoma|Penile Cancer|Penile Diseases|Salivary Gland Cancer|Sarcoma|Thymoma|Urogenital Cancer|Urologic Cancer

Phase 1: Epilepsy|Kidney Cancer|Kidney Diseases|Melanoma|Muscle Spasticity

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT03997370

NRG-GY022

P1

Recruiting

Kidney Cancer|Kidney Diseases

2027-02-06

2023-11-16

Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments

NCT05733689

RANT-GC Trial

P1

Recruiting

Adenocarcinoma|Esophageal Cancer|Gastrointestinal Cancer

2026-02-01

50%

2025-07-09

NCT06953323

WJB001-002-I

P2

Recruiting

Oncology Solid Tumor Unspecified

2029-06-30

12%

2025-08-14

Primary Endpoints|Start Date

NCT07020221

VS-7375-101

P2

Recruiting

Colorectal Cancer|Gastrointestinal Cancer|Pancreatic Cancer|Adenocarcinoma|Pancreatic Ductal Carcinoma|Non-Small-Cell Lung Cancer

2028-12-01

12%

2026-01-24

Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments

NCT06822543

TROPICAL-1

P2

Recruiting

Non-Small-Cell Lung Cancer|Brain Cancer

2028-06-30

2%

2025-09-30

Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status

NCT06630325

STUDY00026643

P2

Active, not recruiting

Sarcoma|Pancreatic Cancer|Breast Cancer|Ovarian Cancer|Prostate Cancer

2027-12-31

12%

2026-01-08

NCT02876107

NCI-2017-00619

P2

Active, not recruiting

Erythema|Breast Cancer|Edema

2027-10-31

12%

2025-10-11

NCT05118854

NCI-2021-10907

P2

Recruiting

Lung Cancer

2027-10-20

12%

2025-10-23

Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments

NCT06351332

ZAP-IT

P2

Active, not recruiting

Male Breast Cancer|Triple Negative Breast Cancer

2027-03-01

12%

2026-01-13

Primary Endpoints|Treatments|Trial Status

NCT06353906

PRIAM

P2

Recruiting

Penile Cancer|Squamous Cell Carcinoma|Urologic Cancer|Urogenital Cancer|Penile Diseases

2026-10-14

12%

2024-08-17

Primary Endpoints|Start Date|Treatments|Trial Status

NCT04159142

CSPC-KAL-BC-16

P2

Recruiting

Triple Negative Breast Cancer

2026-06-20

2%

2025-09-12

Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status

NCT04709276

CHAMP

P2

Active, not recruiting

Prostate Cancer|Neuroendocrine Carcinoma

2026-02-01

2%

2025-09-12

Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status

NCT05832827

Artemis

P2

Recruiting

Thymoma

2025-12-31

12%

2023-10-24

Primary Endpoints|Start Date|Treatments|Trial Status

NCT04681417

RETINO2018

P3

Recruiting

Retinoblastoma

2035-01-20

2024-11-27

Primary Endpoints|Treatments

NCT05991388

Glo-BNHL

P3

Recruiting

Lymphoma, Non-Hodgkin|Lymphoma, B-Cell

2031-05-01

13%

2024-11-27

Primary Endpoints|Treatments

2018-003335-29

2018-003335-29

P3

Active, not recruiting

Other

2029-10-15

2022-03-13

Treatments

2024-520050-38-00

20240178

P3

Not yet recruiting

Small Cell Lung Cancer|Nose Cancer|Tobacco Use Disorder

2029-07-15

NCT07168200

SHR-1316-305

P3

Recruiting

Cervical Cancer

2028-04-01

46%

2025-11-18

Primary Endpoints|Start Date|Treatments|Trial Status

NCT05256225

NCI-2022-01540

P3

Recruiting

Clear Cell Adenocarcinoma|Endometrioid Carcinoma|Endometrial Cancer|Carcinosarcoma|Clear Cell Sarcoma

2027-10-31

2026-02-05

Primary Endpoints|Treatments

2022-502889-24-00

kp-acs-2

P3

Recruiting

Pain Unspecified

2027-08-31

2025-05-02

Treatments

NCT04095364

NRG-GY019

P3

Active, not recruiting

Serous Cystadenocarcinoma|Ovarian Cancer|Peritoneal Cancer|Fallopian Tube Cancer

2027-02-01

2025-05-21

Primary Endpoints|Treatments|Trial Status

NCT04574960

NAUTICAL

P3

Recruiting

Transitional Cell Carcinoma|Bladder Cancer

2026-12-01

2025-07-22

Primary Endpoints

NCT04585490

IRB-54807

P3

Recruiting

Non-Small-Cell Lung Cancer

2026-04-01

45%

2024-04-18

Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments

NCT05468489

ASTRIDE

P3

Active, not recruiting

Small Cell Lung Cancer

2026-02-28

40%

2025-10-23

Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status

NCT04974398

AK105-304

P3

Active, not recruiting

Nasopharyngeal Cancer

2026-02-23

66%

2025-04-15

Primary Endpoints|Treatments